From Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson
This week, a team from Johnson & Johnson joined other world leaders at the Pacific Health Summit to discuss an important and timely topic: vaccines.
Johnson & Johnson made a commitment to vaccines through its recent acquisition of Crucell N.V., a company that is passionate about innovation and about meeting the public health demand for vaccines for children in the world’s poorest countries.
Crucell specializes in the research and development of innovative vaccines especially for infectious diseases that devastate families in the developing world. The company has a track-record for innovation and is passionate about delivering high quality and easy to use vaccines consistently, quickly and at the lowest possible prices in developing markets.
One of their most important products is Quinvaxem® a single-dose, fully-liquid vaccine, developed specifically for use in developing countries. As a pentavalent vaccine, it offers protection against five of the world’s most prevalent childhood diseases-- Hepatitis-B, Haemophilus influenzae type B (Hib), Diphtheria, Tetanus and Pertussis. Since its launch, more than 200 million doses have been distributed worldwide, meaning that more than 60 million children in many of the poorest countries in the world have been fully vaccinated. It is becoming the cornerstone of UNICEF’s childhood vaccine program.
Crucell has been a leader in vaccines, but we want to do more. And as a society, we need to do much more.
First we need to ensure that we continue to deliver high quality and easy to use vaccines consistently, quickly and at appropriate prices across the globe.
Second, we need to continue to focus on innovation and on developing new vaccines for what we call “The Big Three”: HIV, Malaria, and TB, and vaccines for other neglected diseases that affect millions of people around the world.
Third, we need to continue to join forces through partnerships and collaboration—between the public sector, industry, funding agencies, governments, NGOs and others—to ensure that we bring these innovations to save the lives of children all over the world.
Vaccines are the most cost effective way of providing health care to society and preventing human suffering. But no one company or organization can do it alone. We are eager to engage in partnerships that will lead to the development of new solutions to global challenges, including infectious diseases. The Global Alliance for Vaccines and Immunization, or GAVI, Pledging Conference in London, where public and private donors pledged $4.3 billion toward immunizing more than 250 million children by 2015, and venues such as the Pacific Health Summit are helping us make those commitments and connections. The links we built this week will help us – together – to bring solutions for millions of patients and their families around the world.
Paul Stoffels, M.D. Worldwide Chairman, Pharmaceuticals